Spark Therapeutics (NASDAQ: ONCE) was up 9.21% in trading on Wednesday, July 5, 2017, closing at $65.56. $65 has been a resistance point in recent months. The company is scheduled to release interim data from its Phase I/II clinical trial for hemophilia B at the upcoming International Society on Thrombosis and Haemostasis 2017 Congress in Berlin. The company will make three presentations at the conference starting with the first on July 10. SPK-9001 is a gene therapy approach for hemophilia B using a bio-engineered AAV vector delivering a high-activity factor IX transgene.
Well written
Congratulations @bscruggs! You have completed some achievement on Steemit and have been rewarded with new badge(s) :
Click on any badge to view your own Board of Honor on SteemitBoard.
For more information about SteemitBoard, click here
If you no longer want to receive notifications, reply to this comment with the word
STOPHey bscruggs! If you power up your 100 Steem your voting power will increase as well!